Edwards Lifesciences Q1 Sales Up 16.7%, Lifts 2026 Guidance to 9–11% Growth
Edwards Lifesciences delivered Q1 adjusted EPS of $0.78 and revenue of $1.65 billion, outpacing estimates with 16.7% year-over-year sales growth led by TAVR and transcatheter mitral/tricuspid therapies. The company raised 2026 sales growth guidance to 9–11% and EPS outlook to $2.95–3.05, while Q2 projections edged slightly below forecasts.
1. Q1 Financial Performance
Edwards Lifesciences reported first-quarter adjusted EPS of $0.78, beating the $0.73 estimate, and generated $1.65 billion in revenue, surpassing the $1.59 billion consensus. Total sales rose 16.7% year over year, reflecting broad-based strength across its structural heart business.
2. Key Growth Drivers
The transcatheter aortic valve replacement segment accounted for roughly $1.2 billion in Q1 sales, up 14.4% year over year, while the surgical portfolio grew 10.1% to $276.2 million. Transcatheter mitral and tricuspid therapies saw the fastest expansion, surging 59.9% to $175.1 million.
3. Guidance Revision and Outlook
Edwards lifted its full-year 2026 sales growth target to 9–11% from 8–10% and raised EPS guidance to $2.95–3.05. For Q2, the company projects revenue of $1.66–1.74 billion (midpoint $1.70 billion) and adjusted EPS of $0.70–0.76 (midpoint $0.73), slightly below analysts’ forecasts.